Photo from Andrea Apolo/X
Jul 5, 2024, 15:03
Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours
Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at NCI, shared on X:
“Cabozantinib/Nivolumab and Cabozantinib/Nivolumab/Ipilimumab have shown promising efficacy and safety in patients with metastatic urothelial carcinoma, metastatic renal cell carcinoma and rare GU tumors in a dose-escalation phase I study.”
Additional information.
Source: Andrea Apolo/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14